Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C
| Autor: | Yasuyuki Araki, Toshiya Osawa, Hiroshi Ikeda, Toshinari Shimoe, Yoshiaki Iwasaki, Noriaki Hashimoto, Kouichi Takaguchi, Toshitsugu Kobatake, Masaharu Ando, Yasushi Shiratori, Minoru Tomita, Mitsuhiko Kawaguchi, Haruhiko Kobashi, Keiji Kita, Kohsaku Sakaguchi |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Combination therapy Interferon alpha-2 Antiviral Agents chemistry.chemical_compound Interferon Internal medicine Ribavirin medicine Humans Prospective Studies Adverse effect Aged Hepatology business.industry Age Factors Interferon-alpha Hepatitis C Chronic Middle Aged Recombinant Proteins Discontinuation chemistry Immunology Multivariate Analysis Patient Compliance Drug Therapy Combination Female Viral disease business Viral load medicine.drug |
| Zdroj: | Hepatology (Baltimore, Md.). 43(1) |
| ISSN: | 0270-9139 |
| Popis: | In contrast to the United States, Japanese patients with chronic hepatitis C currently treated with interferon are generally 10 to 15 years older. Older patients, however, tend to experience more frequent adverse events. This study was conducted to clarify the effect of patient age on the efficacy and safety of combination therapy. We consecutively enrolled 208 patients with naive chronic hepatitis C. Patients were classified into three groups according to age: younger than 50 years of age (n = 52); 50 to 59 years old (n = 83); and 60 years of age or older (n = 73). Interferon alpha-2b therapy was administered daily for 2 weeks, followed by 3 times per week for 22 weeks, while ribavirin was administered daily. Of the 208 study patients, discontinuation of therapy or dose reduction was required in 116 (56%) and was more frequent in older patient groups: 38%, 48%, and 77% for the |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text